Tubulis today announced the publication of preclinical proof-of-concept data for its novel Alco5 conjugation platform in Nature Communications. The paper describes the company's novel antibody-drug ...

ADC conjugation, redefined. Explore a rapid 3-hour workflow that delivers precise, controlled antibody-drug conjugates for ...

Bacteria are good at evolving to evade efforts to destroy it. But building defenses like antibiotic resistance drains limited ...

Research-backed strategy produces highly homogeneous antibody-drug conjugates (gsADCs) with consistent DAR and tumor ...

Would it be possible to control and even reverse the flow of time in a laboratory setting? While taking a trip back through ...

Bacteria can sneakily evade our best efforts at eradication by developing resistance to various pressures in their ...

This study presents a comprehensive approach for assessing multiple quality attributes of antibody-oligonucleotide conjugates ...

Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ...

The goal with this series was to remove unnecessary complexity and focus purely on the practice learners actually ...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced ...

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was reported, with innovations spanning targets, ...

remove-circle Internet Archive's in-browser bookreader "theater" requires JavaScript to be enabled. It appears your browser does not have it turned on. Please see ...